Optic Neuropathy – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Optic Neuropathy – Pipeline Review, H2 2016’, provides an overview of the Optic Neuropathy pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Optic Neuropathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Optic Neuropathy and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Optic Neuropathy

The report reviews pipeline therapeutics for Optic Neuropathy by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Optic Neuropathy therapeutics and enlists all their major and minor projects

The report assesses Optic Neuropathy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Optic Neuropathy

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Optic Neuropathy

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Optic Neuropathy pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Amgen Inc.

BioAxone BioSciences, Inc.

Inotek Pharmaceuticals Corporation

Ironwood Pharmaceuticals, Inc.

PharmatrophiX, Inc.

Quark Pharmaceuticals, Inc.

Regenera Pharma Ltd.

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Optic Neuropathy Overview 7

Therapeutics Development 8

Pipeline Products for Optic Neuropathy - Overview 8

Pipeline Products for Optic Neuropathy - Comparative Analysis 9

Optic Neuropathy - Therapeutics under Development by Companies 10

Optic Neuropathy - Therapeutics under Investigation by Universities/Institutes 11

Optic Neuropathy - Pipeline Products Glance 12

Late Stage Products 12

Clinical Stage Products 13

Early Stage Products 14

Optic Neuropathy - Products under Development by Companies 15

Optic Neuropathy - Products under Investigation by Universities/Institutes 16

Optic Neuropathy - Companies Involved in Therapeutics Development 17

Amgen Inc. 17

BioAxone BioSciences, Inc. 18

Inotek Pharmaceuticals Corporation 19

Ironwood Pharmaceuticals, Inc. 20

PharmatrophiX, Inc. 21

Quark Pharmaceuticals, Inc. 22

Regenera Pharma Ltd. 23

Optic Neuropathy - Therapeutics Assessment 24

Assessment by Monotherapy Products 24

Assessment by Target 25

Assessment by Mechanism of Action 27

Assessment by Route of Administration 29

Assessment by Molecule Type 31

Drug Profiles 33

BA-240 - Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

IWP-953 - Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

LM-22A4 - Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

Monoclonal Antibodies to Inhibit Sema3A for Glaucoma and Optic Neuropathy - Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

NT-501 - Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

QPI-1007 - Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

RPh-201 - Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

Small Molecule to Inhibit Sema3A for Glaucoma and Optic Neuropathy - Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

Small Molecules for CNS Disorders and Ophthalmology - Drug Profile 45

Product Description 45

Mechanism Of Action 45

R&D Progress 45

Small Molecules for Neurological and Ophthalmological Diseases - Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

Small Molecules to Target O2 Radical and HMGCR for Ophthalmology, Cardiovascular, CNS and Metabolic Disorders - Drug Profile 47

Product Description 47

Mechanism Of Action 47

R&D Progress 47

Synthetic Peptide to Inhibit Connexin 43 for Optic Neuropathy - Drug Profile 49

Product Description 49

Mechanism Of Action 49

R&D Progress 49

trabodenoson - Drug Profile 50

Product Description 50

Mechanism Of Action 50

R&D Progress 50

WSTB-1 - Drug Profile 53

Product Description 53

Mechanism Of Action 53

R&D Progress 53

Optic Neuropathy - Dormant Projects 54

Optic Neuropathy - Product Development Milestones 55

Featured News & Press Releases 55

Jul 29, 2016: Quark Pharmaceuticals Awarded Key Patent for QPI-1007 Ocular Neuroprotectant 55

Jun 23, 2016: Biocon, Quark Announce Initiation of Pivotal Phase II/III Study of QPI-1007 in Rare Eye Disease in India 55

Apr 26, 2016: Inotek Pharmaceuticals Announces Poster Presentations on Trabodenoson at the ARVO 2016 Annual Meeting 56

Mar 14, 2016: Quark Pharmaceuticals Doses First Patient in Pivotal Phase III Study of RNAi-Based Therapeutic QPI-1007 for Eye Indications 56

Oct 27, 2015: Quark Pharmaceutical Announces Initiation of Patient Recruitment for Global Pivotal Study of QPI-1007 in NAION 57

Feb 28, 2014: Regenera Pharma has been initiated the Phase IIa study in patients with chronic Ischemic Optic Neuropathy 57

Apr 30, 2011: Regenera Pharma received the final report of its safety study in minipigs and is moving to human studies 57

Appendix 58

Methodology 58

Coverage 58

Secondary Research 58

Primary Research 58

Expert Panel Validation 58

Contact Us 58

Disclaimer 59

List of Tables

List of Tables

Number of Products under Development for Optic Neuropathy, H2 2016 8

Number of Products under Development for Optic Neuropathy – Comparative Analysis, H2 2016 9

Number of Products under Development by Companies, H2 2016 10

Number of Products under Investigation by Universities/Institutes, H2 2016 11

Comparative Analysis by Late Stage Development, H2 2016 12

Comparative Analysis by Clinical Stage Development, H2 2016 13

Comparative Analysis by Early Stage Development, H2 2016 14

Products under Development by Companies, H2 2016 15

Products under Investigation by Universities/Institutes, H2 2016 16

Optic Neuropathy – Pipeline by Amgen Inc., H2 2016 17

Optic Neuropathy – Pipeline by BioAxone BioSciences, Inc., H2 2016 18

Optic Neuropathy – Pipeline by Inotek Pharmaceuticals Corporation, H2 2016 19

Optic Neuropathy – Pipeline by Ironwood Pharmaceuticals, Inc., H2 2016 20

Optic Neuropathy – Pipeline by PharmatrophiX, Inc., H2 2016 21

Optic Neuropathy – Pipeline by Quark Pharmaceuticals, Inc., H2 2016 22

Optic Neuropathy – Pipeline by Regenera Pharma Ltd., H2 2016 23

Assessment by Monotherapy Products, H2 2016 24

Number of Products by Stage and Target, H2 2016 26

Number of Products by Stage and Mechanism of Action, H2 2016 28

Number of Products by Stage and Route of Administration, H2 2016 30

Number of Products by Stage and Molecule Type, H2 2016 32

Optic Neuropathy – Dormant Projects, H2 2016 54

List of Figures

List of Figures

Number of Products under Development for Optic Neuropathy, H2 2016 8

Number of Products under Development for Optic Neuropathy – Comparative Analysis, H2 2016 9

Number of Products under Development by Companies, H2 2016 10

Number of Products under Investigation by Universities/Institutes, H2 2016 11

Comparative Analysis by Clinical Stage Development, H2 2016 13

Comparative Analysis by Early Stage Products, H2 2016 14

Assessment by Monotherapy Products, H2 2016 24

Number of Products by Targets, H2 2016 25

Number of Products by Stage and Targets, H2 2016 25

Number of Products by Mechanism of Actions, H2 2016 27

Number of Products by Stage and Mechanism of Actions, H2 2016 27

Number of Products by Routes of Administration, H2 2016 29

Number of Products by Stage and Routes of Administration, H2 2016 29

Number of Products by Molecule Types, H2 2016 31

Number of Products by Stage and Top 10 Molecule Types, H2 2016 31

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports